Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $649000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 44.29% year-over-year to $649000.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 28.59% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 7.18% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $649000.0, down from $682000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for CRBU reached as high as $1.6 million in Q3 2023 and fell as low as $308000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $786352.9 across 5 years, with a median of $682000.0 in 2025.
• Across the five-year window, Depreciation & Amortization (CF) surged 250.89% in 2023 and plunged 46.39% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $506000.0 in 2022, then soared by 46.25% to $740000.0 in 2023, then surged by 60.0% to $1.2 million in 2024, then plunged by 42.4% to $682000.0 in 2025, then declined by 4.84% to $649000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $649000.0 in Q1 2026, $682000.0 in Q4 2025, and $631000.0 in Q3 2025.